^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    recombinant human thyroid stimulating hormone for injection (rhTSH)

    i
    Other names: rhTSH
    Associations

    News

    Trials
    Company:
    Suzhou Zelgen
    Drug class:
    Thyroid hormone receptor agonist
    Associations

    News

    Trials
    almost2years
    Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal (clinicaltrials.gov)
    P3, N=201, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jul 2023 | Trial primary completion date: Jun 2024 --> Jul 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    over2years
    The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    TG (Thyroglobulin)
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    over2years
    Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer (clinicaltrials.gov)
    P3, N=328, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    almost3years
    The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2023 --> Aug 2023
    Enrollment closed • Trial primary completion date
    |
    TG (Thyroglobulin)
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    3years
    The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (clinicaltrials.gov)
    P2, N=120, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
    Trial completion date • Trial primary completion date
    |
    TG (Thyroglobulin)
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    over3years
    Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study. (PubMed, Eur J Nucl Med Mol Imaging)
    The ZGrhTSH held the promise to be a safe and effective modality in facilitating RAI uptake and serum thyroglobulin stimulation, with better QoL of patients with DTC compared with L-T withdrawal.
    P1/2 data • Journal
    |
    TG (Thyroglobulin)
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    4years
    The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (clinicaltrials.gov)
    P2, N=120, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    TG (Thyroglobulin)
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)
    over4years
    The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (clinicaltrials.gov)
    P2, N=120, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Oct 2021 | Trial primary completion date: Jul 2023 --> Sep 2021
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    TG (Thyroglobulin)
    |
    recombinant human thyroid stimulating hormone for injection (rhTSH)